Literature DB >> 3945892

Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy.

P M Lehti, H S Moseley, K Janoff, K Stevens, W S Fletcher.   

Abstract

Soft tissue sarcomas continue to present problems with both local control of disease and death from distant metastases after accepted surgical therapy. Multimodality management has been established in the literature to be superior to traditional therapy of wide excision or amputation. The results of the treatment of 64 patients at Oregon Health Sciences University using regional hyperthermic perfusion with l-phenylalanine mustard and actinomycin D, wide local excision and external radiation therapy are reviewed. Histologic tumor types included: 19 liposarcomas, 14 malignant fibrous histiocytomas, eight fibrosarcomas, five leiomyosarcomas, four malignant schwannomas and 14 other sarcomas of the extremities. Minimum follow-up study has been 24 months and the mean follow-up time is more than five years. One-third of the patients presented with local recurrent disease after unsuccessful primary treatment. Over-all local recurrence for all patients treated by a combination of the aforementioned modalities was 3.4 per cent at two years and 11.1 per cent at five years. The over-all survival rate for all patients was 88 per cent at two years and 67 per cent at five years compared with a published over-all five year survival rate of 41 per cent. Patients with malignant fibrous histiocytomas had both two and five year local recurrence rates of 7.7 per cent and survival rates at two and five years of 79 and 63 per cent, respectively. This is compared with a previously published over-all five year survival rate with malignant fibrous histiocytomas of 46 per cent. The results with the treatment of liposarcomas were also superior to the published literature. Not only are the treatment results with regional hyperthermic perfusions excellent for both primary and locally recurrent sarcomas of the extremities, but limbs previously considered unsalvagable can be spared.

Entities:  

Mesh:

Year:  1986        PMID: 3945892

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  8 in total

1.  [Improved intraoperative leak control in cytostatic drug isolation perfusion of tumors of the extremities].

Authors:  M Manner; H Sinn; H Bubeck; C Kettelhack; P Schlag
Journal:  Langenbecks Arch Chir       Date:  1990

Review 2.  [Bone and soft tissue tumors--general strategy of therapy].

Authors:  H P Bruch
Journal:  Langenbecks Arch Chir       Date:  1987

3.  Hyperthermic isolation perfusion of the limbs with cytostatics after surgical excision of sarcomas.

Authors:  F J Lejeune; D Lienard; P Ewalenko
Journal:  World J Surg       Date:  1988-06       Impact factor: 3.352

4.  The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities.

Authors:  F Di Filippo; A M Calabrò; A Cavallari; S Carlini; G L Buttini; F Moscarelli; F Cavaliere; L Piarulli; R Cavaliere
Journal:  World J Surg       Date:  1988-06       Impact factor: 3.352

5.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.

Authors:  A M Eggermont; H Schraffordt Koops; J M Klausner; B B Kroon; P M Schlag; D Liénard; A N van Geel; H J Hoekstra; I Meller; O E Nieweg; C Kettelhack; G Ben-Ari; J C Pector; F J Lejeune
Journal:  Ann Surg       Date:  1996-12       Impact factor: 12.969

Review 6.  Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.

Authors:  A M Eggermont; T L ten Hagen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

Review 7.  Isolated limb perfusion for extremity sarcoma.

Authors:  B W Feig
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

8.  Feasibility of chemosensitivity testing in soft tissue sarcomas.

Authors:  Marcus Lehnhardt; Thomas Muehlberger; Cornelius Kuhnen; Daniel Brett; Hans U Steinau; Hamid Joneidi Jafari; Lars Steinstraesser; Oliver Müller; Heinz H Homann
Journal:  World J Surg Oncol       Date:  2005-04-18       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.